Actively Recruiting
Evaluate the Therapy of Large Ovarian Endometrioma
Led by University Hospital, Lille · Updated on 2025-12-23
62
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Large ovarian endometriomas, which occur in 23 to 55% of cases, can cause pelvic pain, reduced fertility, and decreased ovarian reserve. There is currently no established best treatment to limit recurrence, preserve fertility, and maintain ovarian reserve. Researchers at Lille University Hospital are evaluating a protocol involving laparoscopic drainage combined with hormonal therapy for women of childbearing age with endometriomas measuring 6 cm or larger. This observational and prospective study focuses on women aged 18 to 40 with large endometriomas. The treatment being studied is cyst drainage followed by a GnRH agonist hormone therapy. The aim is to assess if this approach can reduce cyst recurrence, protect ovarian reserve, and evaluate effects on anti-Müllerian hormone levels. Participants will be monitored to measure the recurrence rate of cysts 3 cm or larger at 3 months using MRI or pelvic ultrasound. Researchers will also evaluate postoperative ovarian reserve and track the number of re-operations by 4 months. The study involves clinical imaging and hormone tests to understand treatment impact over the follow-up period.
CONDITIONS
Brief Title
The Therapy of Large Endometrioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Endometrioma size 6 cm or larger determined by MRI or ultrasonography
- Women with isolated endometrioma or other extraovarian endometriosis such as peritoneal, infiltrating endometriotic lesions, and adenomyosis
- Single or bilateral cysts
- Female participants aged 18 to 40 years
You will not qualify if you...
- Cysts with radiographic or macroscopic atypia observed in laparoscopy
- Pregnancy
- Contraindication to GnRH agonist treatment (Enantone� 3.75 mg or Decapeptyl� 3 mg)
- Contraindication to laparoscopy
- Contraindication to general anesthesia
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 months
Participants are monitored for recurrence of ovarian endometrioma and impact on ovarian reserve using MRI or pelvic ultrasonography.
Visits at 3 and 4 months for imaging and assessment
Trial Site Locations
Total: 1 location
1
Hop Jeanne de Flandre Chu Lille
Lisle-sur-Tarn, France, 59037
Actively Recruiting
Research Team
C
Chrytèle RUBOD, MD,PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here